Wells Fargo Initiates Coverage of Globus Medical (GMED) with an Overweight Rating

Globus Medical, Inc. (NYSE:GMED) is one of the 8 Best Debt Free Stocks to Buy Right Now. On March 18, 2026, Wells Fargo assumed coverage of Globus Medical, Inc. (NYSE:GMED) with an Overweight rating and a $104 price target, while maintaining its rating, price target, and estimates.

Last month, Globus Medical, Inc. (NYSE:GMED) reported fourth-quarter EPS of $1.28, above the 96c consensus estimate, with revenue of $826.4M compared to the $803.29M consensus. Chief Executive Officer Keith Pfeil said momentum “accelerated in the fourth quarter,” pointing to double-digit sales and earnings growth and expansion across the company’s portfolio, including its spine business, supported by disciplined execution. Pfeil added that the company is focused on sustaining growth through product launches, expanding its sales force, and improving outcomes through its surgical ecosystem.

Globus Medical, Inc. (NYSE:GMED) raised its FY26 EPS outlook to $4.40-$4.50 from $4.30-$4.40, above the $4.24 consensus, and expects FY26 revenue of $3.18B-$3.22B compared to the $3.16B consensus.

Globus Medical, Inc. (NYSE:GMED) develops and commercializes healthcare solutions for musculoskeletal disorders globally.

While we acknowledge the risk and potential of GMED as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than GMED and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None.  Follow Insider Monkey on Google News.